Literature DB >> 20387097

Stability kinetics of influenza vaccine coated onto microneedles during drying and storage.

Yeu-Chun Kim1, Fu-Shi Quan, Richard W Compans, Sang-Moo Kang, Mark R Prausnitz.   

Abstract

PURPOSE: This study sought to determine the effects of microneedle coating formulation, drying time and storage time on antigen stability and in vivo immunogenicity of influenza microneedle vaccines.
METHODS: The stability of inactivated influenza virus vaccine was monitored by hemagglutination (HA) activity and virus particle aggregation as a function of storage time and temperature with or without trehalose. In vivo immunogenicity of inactivated influenza vaccines coated onto microneedles was determined in mice by virus-specific antibody titers and survival rates.
RESULTS: In the absence of trehalose, HA activity decreased below 10% and to almost zero after 1 h and 1 month of drying, respectively. Addition of trehalose maintained HA activity above 60% after drying and above 20% after 1 month storage at 25°C. Loss of HA activity generally correlated with increased virus particle aggregation. Administration of microneedles coated with trehalose-stabilized influenza vaccine yielded high serum IgG antibody titers even after 1 month storage, and all animals survived with minimal weight loss after lethal challenge infection.
CONCLUSIONS: Inactivated influenza virus vaccine coated on microneedles with trehalose significantly improved the HA activity as well as in vivo immunogenicity of the vaccine after an extended time of storage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20387097      PMCID: PMC2916971          DOI: 10.1007/s11095-010-0134-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  41 in total

Review 1.  The injection century: massive unsterile injections and the emergence of human pathogens.

Authors:  E Drucker; P G Alcabes; P A Marx
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

Review 2.  Seasonal influenza vaccines: evolutions and future trends.

Authors:  Arnold S Monto; Suzanne E Ohmit
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

3.  Inulin glasses for the stabilization of therapeutic proteins.

Authors:  W L Hinrichs; M G Prinsen; H W Frijlink
Journal:  Int J Pharm       Date:  2001-03-14       Impact factor: 5.875

4.  Cold chain status at immunisation centres in Ethiopia.

Authors:  Y Berhane; M Demissie
Journal:  East Afr Med J       Date:  2000-09

Review 5.  Microneedle-based vaccines.

Authors:  Mark R Prausnitz; John A Mikszta; Michel Cormier; Alexander K Andrianov
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

6.  Improved influenza vaccination in the skin using vaccine coated microneedles.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

7.  Effect of microneedle design on pain in human volunteers.

Authors:  Harvinder S Gill; Donald D Denson; Brett A Burris; Mark R Prausnitz
Journal:  Clin J Pain       Date:  2008-09       Impact factor: 3.442

8.  Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge.

Authors:  Qiyun Zhu; Vladimir G Zarnitsyn; Ling Ye; Zhiyuan Wen; Yulong Gao; Lei Pan; Ioanna Skountzou; Harvinder S Gill; Mark R Prausnitz; Chinglai Yang; Richard W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

9.  Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Dae-Goon Yoo; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

10.  Transdermal influenza immunization with vaccine-coated microneedle arrays.

Authors:  Dimitrios G Koutsonanos; Maria del Pilar Martin; Vladimir G Zarnitsyn; Sean P Sullivan; Richard W Compans; Mark R Prausnitz; Ioanna Skountzou
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more
  31 in total

1.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

Review 2.  Microneedle Coating Methods: A Review with a Perspective.

Authors:  Rohan S J Ingrole; Harvinder Singh Gill
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

3.  Stability of influenza vaccine coated onto microneedles.

Authors:  Hyo-Jick Choi; Dae-Goon Yoo; Brian J Bondy; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Biomaterials       Date:  2012-02-21       Impact factor: 12.479

4.  Long-term stability of influenza vaccine in a dissolving microneedle patch.

Authors:  Matthew J Mistilis; Jessica C Joyce; E Stein Esser; Ioanna Skountzou; Richard W Compans; Andreas S Bommarius; Mark R Prausnitz
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

5.  Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Cheng He; Changbo Ou; Li Wang; Ying-Chun Wang; Hao Feng; Han Zhang; Mark R Prausnitz; Richard W Compans
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

6.  Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.

Authors:  Yeu-Chun Kim; Jae-Min Song; Aleksandr S Lipatov; Seong-O Choi; Jeong Woo Lee; Ruben O Donis; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Eur J Pharm Biopharm       Date:  2012-04-03       Impact factor: 5.571

7.  Enabling skin vaccination using new delivery technologies.

Authors:  Yeu-Chun Kim; Mark R Prausnitz
Journal:  Drug Deliv Transl Res       Date:  2011-02-01       Impact factor: 4.617

8.  Measles vaccination using a microneedle patch.

Authors:  Chris Edens; Marcus L Collins; Jessica Ayers; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2012-10-05       Impact factor: 3.641

Review 9.  The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.

Authors:  Kamran Badizadegan; James L Goodson; Paul A Rota; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2020-03-17       Impact factor: 5.217

Review 10.  Microneedle patches for vaccination in developing countries.

Authors:  Jaya Arya; Mark R Prausnitz
Journal:  J Control Release       Date:  2015-11-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.